Clinical Trial Update: A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II study evaluating the combination of MGCD0103 with azacitidine in high-risk myelodysplastic syndrome or acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• MGCD0103 (mocetinostat)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Myelodysplastic Syndrome, Acute Myelogenous Leukemia | Phase 1, Phase 2 | Status: COMPLETED